PERIPHERAL T-CELL LYMPHOMAS ROMIDEPSIN UPDATES


Andrei Shustov, M.D.


University of Washington School of Medicine Fred Hutchinson Cancer Research Center Seattle WA




ROMIDEPSIN IN RELAPSED/REFRACTORY PTCL

Best Response	Central Review (IWC)				
Dest Response	N (130)	%			
Overall response (CR + PR)	33	25%			
Complete response (CR+CRu)	19	15%			
Partial response (PR)	14	11%			







Coiffier B. et al. J Clin Onc 2012; 30:631-636

ROMIDEPSIN (2009): WHERE DO WE TAKE IT

Palliative intent therapy

- Combination with other single agent
 - Romidepsin and pralatrexate
 - Romidepsin and duvelisib
 - Romidepsin and 5-Azacytidine
- Curative intent therapy
 - Combination with multiagent platforms
 - Newly Dx PTCL
 - Ro-CHOP
 - Relapse-Refractory PTCL
 - Ro-ICE
 - Post-HCT maintenance

FRONTLINE PTCL THERAPY: ROMIDEPSIN + CHOP

ROMIDEPSIN IN COMBINATION WITH CHOP IN PATIENTS WITH NEWLY-DIAGNOSED PTCL: PHASE 1B/2 DOSE-FINDING STUDY

Ro-CHOP: PATIENT AND DISEASE CHARACTERISTICS

	Total
	N=37
Age*, years	57 (30–77)
Gender, n	20 M / 17 F
aalPI score >1, n (%)	27 (73)
Stage III/IV disease, n (%)	35 (95)
Diagnosis	
sALCL, ALK-, n (%)	2 (5)
cALCL, n (%)	1 (3)
Mycosis Fungoides, n (%)	1(3)
Peripheral T-cell lymphoma, follicular type, n (%)	1 (3)
Other peripheral T-cell lymphomas, n (%)	2 (6)
Peripheral T-cell lymphoma NOS, n	9 (24)
Angioimmunoblastic T-cell lymphoma, n	15 (41)
Precursor T-lymphoblastic lymphoma, n (%)	1 (3)
Enteropathy-associated T-cell lymphoma, n	1 (3)

Ro-CHOP: GRADE 3-4 TEAE >10%

TEAE per CTCAE 4.0	Total N=37
Anemia n (%)	16 (43)
Thrombocytopenia n (%)	29 (78)
Neutropenia	33 (89)
Lymphopenia	16 (43)
Nausea	7 (19)
Vomiting	4 (11)
Febrile neutropenia	6 (17)
Weight loss	4 (11)
Transaminase elevation	4 (11)
Hypophosphatemia	4 (11)
Asthenia	4 (11)


Ro-CHOP: CLINICAL RESPONSE

Total

(N=35) Objective Response, n (%) 24 (68%) Complete Remission 18 (51%) Partial Remission 6 (17%)

DLT reached at the dose of Romidepsin of 12 mg/sqm on days 1 and 8

Phase III trial of Ro-CHOP vs CHOP nears completion of accrual.



* Response per investigator at end of combination treatment (Cycle 6) or at latest assessment for 3 patients who discontinued prior to Cycle 6 (Cheson 2007)

Dupuis, J. et al. Lancet Haematol. 2015; 2:e160-65.

RELAPSED/REFRACTORY PTCL THERAPY: ROMIDEPSIN + ICE

A PHASE I STUDY OF ROMIDEPSIN AND IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (ICE) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

Paolo Strati, MD

T-Cell Lymphoma Team

PI: Michelle Fanale, MD

SALVAGE REGIMENS IN PTCL

REGIMEN	ORR (%)	CR rate (%)
Ifosfamide Carboplatin Etoposide	70	35
Gemcitabine Cisplatin Methylprednisolone	69	19
Gemcitabine Oxaliplatin Dexamethasone	38	8
Ifosfamide Methotrexate Etoposide	28	15



Primary

- Safety profile
- MTD




- ORR
- CR

TREATMENT SCHEMA: "EVERYTHING IS BIG IN TEXAS"

Treatment Schema

Romidepsin+I	CE treatment dosing	Every 2 weeks		
Day	Drug	Dose Level	Infusion Time	(ANC > 1, PLT > 75)
1 and 4	Romidepsin	Level 1 = 8 mg/m ² Level 2 = 10 mg/m ² Level 3 = 12 mg/m ²	IV over 4 hours	
1	Ifosfamide + MESNA	5 gm/m ² for both	IV infusion over 24 hrs	2-6 cycles
2	MESNA	2 gm/m ²	IV infusion over 12 hrs	1
1	Carboplatin	Target AUC = 5 mg/mL/min (Maximum dose of 750 mg)	IV over 1 hr	Neulasta or Neupogen
1 through 3	Etoposide	100 mg/m²/day	IV over 2 hrs daily x 3 doses	1



P. Strati ASH-2017

DOSE ESCALATION (BAYESIAN CRM)

Dose Escalation

DLT (CTCAE v4.0)

- During cycle 1
- Non-heme: G > 3 AE
- Heme: G4 AE for > 14 days

MTD

- dose at which 20% of pts have a DLT

			Number of patients treated at current dose														
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	0	E	E	E	E	E	E	E	E	E	E	E	E	E	E	E	E
	1	DU	D	s	s	S	s	S	S	E	E	E	E	E	E	E	E
.	2		DU	DU	D	S	s	S	S	S	S	S	s	S	s	s	s
Ē.	3			DU	DU	DU	DU	D	S	S	S	S	s	S	s	s	s
(DLTs)	4				DU	DU	DU	DU	DU	DU	D	S	S	S	S	S	S
60 60	5					DU	DU	DU	DU	DU	DU	DU	DU	DU	S	S	S
limiting toxicities	6						DU										
жi	7							DU									
ž.	8								DU								
, Ĕ	9									DU							
ΞĒ.	10										DU						
Number of dose li							4			DU	DU	DU	DU	DU	DU		
ð	12		 Stay 	at the	current	dose							DU	DU	DU	DU	DU
0.	13				to the dose is									DU	DU	DU	DU
- de	14	N	(TD = 2	0%											DU	DU	DU
Ε. ·	15	Sample Size = 18 Epsilon1 = 0.05												DU	DU		
Z ·	16		pallon 2														DU
-	17																
	18																

PATIENTS' CHARACTERISTICS

Patients (n=22)	Number	Patients (n=22)	Number (percentage),
	(percentage),		median [range]
		Previous regimens (n)	1 [1-2]
	median [range]	Previous regimen > 1	1 (5)
Median time from	6 [2-45]	Latest regimen: CHOP	10 (45)
diagnosis (months)		CHOEP	6 (27)
Age (years)	58 [19-68]	EPOCH	2 (9)
Age > 65 years	4 (18)	HCVAD	2 (9)
Males	15 (68)	B-CHP	2 (9)
	· · · · · · · · · · · · · · · · · · ·	Previous autologous SCT	2 (10)
Diagnosis: PTCL-NOS	9 (40)	Previous radiation therapy	2 (10)
AITL	8 (36)	Response to previous regimen:	
ALK+ ALCL	3 (14)	CR	5 (23)
NK/TCL	1 (5)		
HSTL	1 (5)	PR	3 (14)
Ann Arbor stage I	0 (0)	SD	2 (9)
II	4 (18)		2 (0)
111	7 (32)	PD	12 (54)
IV	11 (50)	Relapsed < 6 months	19 (86)

Ro-ICE: DOSE LEVEL DISTRIBUTION

Patients (n=18*)	Patients (n)	Total cycles (n)
Dose level 1 (8 mg/m2)	2	7
Dose level 2 (10 mg/m2)	15	39
Dose level 3 (12 mg/m2)	1	1

(*) 4 patients did not start treatment consent withdrawal (2), lack of insurance (1), MI (1)

Median time between subsequent cycles was 21 days (range, 14-33 days) Median time on study was 2 months (range, 1-13 months)

REASONS FOR TREATMENT DISCONTINUATION

Patients (n=18)	Number (%)
SCT	12 (67)
Toxicity*	4 (23)
Lack of response	1 (5)
Withdrawal	1 (5)

(*): thrombocytopenia, AKI, allergy, ototoxicity

Ro-ICE: GRADE **3-4 TEAE > 5%**

	Numbe
Patients (n=18)	r (%)
Hematological tox	icity
Thrombocytopenia	15 (83)
Anemia	9 (50)
Neutropenia	8 (44)
TTP	1 (5.5)
Febrile neutropenia	1 (5.5)


	Numbe
Patients (n=18)	r (%)
Non-hematological to	xicity
Fatigue	6 (33)
Nausea/vomiting	6 (33)
Infections	5 (28)
Dyspnea	3 (17)
Transaminitis	2 (11)
Constipation	1 (5.5)
Arrhythmia	1 (5.5)
Confusion	1 (5.5)
Allergy	1 (5.5)
Acute renal insufficiency	1 (5.5)
Ototoxicity	1 (5.5)

RO-ICE: EFFICACY ASSESSMENT

Patients (n=15*)	Number (%)
ORR	14 (93)
CR	12 (80)
PR	2 (13)
NR	1 (7)

(*) 3 pts stopped treatment before response assessment Allergy, ototoxicity and thrombocytopenia

OVERALL SURVIVAL




Patients (n=18)	Number (%)
Progression	6 (33)
Pneumomia (PD)	2 (10)
T-AML (CR)	1 (5)
AKI (CR)	1 (5)


RO-ICE VS. ICE VS. ROMIDEPSIN

REGIMEN	ORR (%)	CR rate (%)
ICE	70	35
Romidepsin	25	15
ICE + romidepsin	93	80

Toxicity ICE + romidepsin = ICE > romidepsin

PRALATREXATE AND ROMIDEPSIN ARE HIGHLY SYNERGISTIC ACROSS IN VIVO MODELS OF TCL





Synergy demonstrated by activity seen at lower doses of each drug compared to MTD of each

	Estimated log-intensity (p-value)					
Treatment group	4 th day	8 th day	11 th day	14 th day		
Control	7.78 (<0.05)	8.09 (<0.05)	8.32 (<0.05)	8.55 (<0.05)		
Romidepsin	7.75 (<0.05)	8.00 (<0.05)	8.20 (<0.05)	8.39 (<0.05)		
Pralatrexate	7.58 (0.02)	7.74 (<0.05)	7.86 (<0.05)	7.98 (<0.05)		
Romidepsin + Pralatrexate	7.49	7.24	7.06	6.87		



Jain, S. et al. Clinical Cancer Research, 2015. 21(9): 2096-2106

EVIDENCE FOR SELECT EMERGING DOUBLETS IN PTCL: PURE TARGETING OF EPIGENETIC OPERATIONS








SUMMARY OF RESPONSE DATA: PRALATREXATE ROMIDEPSIN PHASE 1


Parameter	Number
Total # of Patients (evaluable)	29 (23)
ORR (all)	13/23 (57%)
ORR non-TCL	3/9 (33%)
ORR T-Cell	10/14 (71%)
T-Cell CR	4/10 (40%)
T-Cell PR	6/10 (60%)

WATERFALL PLOT OF PATIENTS WITH MEASURABLE DISEASE ON PRALATREXATE / ROMIDEPSIN



Amengual JA et al; Blood 2017

EPIGENETIC DRUGS SIGNIFICANTLY AFFECT THE MALIGNANT PHENOTYPE




Marchi E. et al; BJH 2015 Kalac M. et al; Blood 2011

Illumina Human HT-12 v4 Expression BeadChip microarrays

>47,000 probes Cell lines: HH, H9, P12, PF 382 Treatment schedules: D, R, R+D GEP timing: 48 hours of incubation

Data analysis: GeneSpring GX 11.0





Columbia University Medical Center

EVIDENCE FOR SELECT EMERGING DOUBLETS IN PTCL: PURE TARGETING OF EPIGENETIC OPERATIONS

Romidepsin

(Oral) 5-Azacytidine





NewYork-Presbyterian The University Hospital of Columbia and Cornell

PHASE 1-2 STUDY OF ORAL 5-AZACYTIDINE AND ROMIDEPSIN IN LYMPHOMA

Parameter	Number
Total # of Pts. (evaluable)	26 (23)
ORR (all)	7/23 (30%)
ORR non-PTCL	3/18 (17%)
ORR T-Cell	4/5 (80%)

- Most significant toxicity is Grade
 1-2 nausea due to azacytidine
- One DLT in cohort 7 led to expansion
- Albeit early, responses in PTCL appear more than what is seen in BCL
- PK analysis pending
- Methylation assays being conducted on all patients (PBL) and select tissue

IN VITRO, IN VIVO, AND PARALLEL PHASE I EVIDENCE SUPPORT THE SAFETY AND ACTIVITY OF DUVELISIB, A PI3K Δ,Γ INHIBITOR, IN COMBINATION WITH ROMIDEPSIN OR BORTEZOMIB IN RELAPSED/REFRACTORY T-CELL LYMPHOMA

Alison J. Moskowitz MD, Raphael Koch MD, Neha Mehta-Shah MD, Patricia Myskowski MD, Meenal Kheterpal MD, Ahmet Dogan MD PhD, Theresa Davey MPAS, Natasha Galasso BA, Marzouk Evan BA, Monica Shah BA, Nivetha Ganesan BS, Lakeisha Lubin BS, Youn H. Kim MD, Michael Khodadoust MD PhD, Timothy Almazan MD, Julia Dai MD, Eric D. Jacobsen MD, David M. Weinstock MD, and Steven M. Horwitz MD




Memorial Sloan Kettering Cancer Center..






Washington University in St. Louis School of Medicine

SYNERGY DEMONSTRATED BETWEEN DUVELISIB AND ROMIDEPSIN IN DUVELISIB-RESISTANT CELL LINE



PARALLEL PHASE I STUDIES OF DUVELISIB PLUS ROMIDEPSIN OR BORTEZOMIB 3+3 DESIGN WITH DOSE EXPANSION AT MTD




ARM A: DOSE ESCALATION AND EXPANSION

ARM A – Duv			
	Romidepsin days 1, 8, 15		
1	10 mg/m²	25mg BID	
2	10 mg/m²	50mg BID	
3	10 mg/m²	75mg BID	

MTD Arm A Dose Level 3; Romidepsin (10mg/m2 IV) + Duvelisib (75mg PO, BID)

ROMIDEPSIN + DUVELISIB: ALL GRADE 3,4 AND >20% ALL



2 deaths unrelated to treatment:

- Diffuse alveolar hemorrhage following allogeneic stem cell transplant
- Sepsis in setting of disease progression

ROMIDEPSIN + DUVELISIB: EFFICACY

ARM A – Duvelisib + Romidepsin - Response								
Dose Level		Evaluable for onse/Total	Overall response			Partial Response		
1		4/4	2		0		2	
2		3/4	2		1		1	
3		8/8	5		3		2	
TOTAL		15/16	9 (60%)	4 (27%)		5 (33%)		
CTCL vs.								
PTCL		#pts Evaluable for Response	Overall Respon Rate	se	Complet Respons		Partial Response	
		Evaluable	· · · · · · · · · · · · · · · · · · ·	se				
PTCL	•	Evaluable for Response	Rate	se	Respons	e	Response	
PTCL CTCL	•	Evaluable for Response 4	Rate 2 (50%)	se	Respons	e	Response 2 (50%)	

Adverse Events of Special Interest (LFTs)

Duvelisib + Romidepsin				Sing	le Agent [Duvelisib	
	n=16				n=210		
AE	Any grade		AE	Any grade	Gr. 3 & 4		
ALT	2 (12.5)	0 (0)		ALT	81 (38.6)	41 (19.5)	
AST	2 (12.5)	0 (0)		AST	79 (37.6)	32 (15.2)	

Courtesy of S. Horwitz ASH-2017

Flinn et al., Bood 2017

ROMIDEPSIN (2009): WHERE DID WE TAKE IT

No new label or a combination a decade later; lesson learned?

Ro-CHOP phase I: increased toxicity of CHOP, added efficacy unknown; phase III final trial results pending

Ro-ICE phase I: minimal added toxicity to ICE, promising CR rate; need confirmatory trial

Novel doublets with pralatrexate, 5-azacytidine, and duvelisib increased ORR and CR rates; confirmatory studies needed; might be the initial step towards new multiagent platform for newly Dx and R/R PTCL

THANK YOU